Transcend can deliver an anti-amyloid beta antibody to the brain
VANCOUVER, CANADA I November 1, 2011 I biOasis Technologies Inc. (TSX-V: BTI.V – News) today announced test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain which showed that Transcend can deliver an anti-amyloid beta antibody to the brain. The work was conducted on behalf of the Company by the National Research Council of Canada (NRC). Anti-amyloid beta antibodies are currently in clinical trials for the treatment of Alzheimer’s disease (AD). The passive immunization of AD patients using antibodies directed at the Ass peptide is a potential therapeutic strategy aimed at reducing amyloid plaques in the brain. The plaques, consisting of insoluble amyloid ss protein are thought to be responsible for the neuronal cell death and the associated cognitive impairment seen in AD patients. The challenge in using anti-amyloid ss antibodies (and monoclonal antibodies in general) is that these proteins penetrate the blood brain barrier poorly. Approaches that can efficiently deliver these antibodies into the brain may be the key for their use in the treatment of AD.
"There are a number of pharmaceutical companies that are in both early and late stage clinical trials studying anti-amyloid ss antibodies as potential treatments for AD. biOasis has shown over the past several months that its Transcend platform can deliver antibodies (in the case of Herceptin® and now anti-amyloid ss) across the blood-brain barrier in observed higher levels than the antibodies on their own," said Rob Hutchison, CEO. "It may well be that anti-amyloid ss antibodies can provide a treatment for AD, so long as sufficient levels of the antibody can be delivered into the brain. Our Transcend blood-brain delivery platform may play a key role in facilitating the delivery of these antibodies and potentially contribute to the development of new therapeutic approaches to treating AD."
ABOUT TRANSCEND
biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood-brain barrier – Transcend. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation to a range of small molecule and biologic therapeutics. Overcoming the difficulty of delivering therapeutic agents to specific regions of the brain presents a major challenge to treatment of most brain disorders. In its neuroprotective role, the blood-brain barrier functions to hinder the delivery of many potentially important diagnostic and therapeutic agents to the brain. Therapeutic molecules and genes that might otherwise be effective in diagnosis and therapy do not cross the BBB in adequate amounts. It is widely reported that over 95% of all Therapeutic molecules do not cross the blood-brain barrier. To address the unmet clinical need to transport drugs across the blood-brain barrier biOasis intends to license Transcend to multiple corporate partners.
ABOUT BIOASIS:
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing
Cognitest™, a blood test for the diagnosis of Alzheimer’s disease. biOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.
SOURCE: biOasis Technologies
Post Views: 30
Transcend can deliver an anti-amyloid beta antibody to the brain
VANCOUVER, CANADA I November 1, 2011 I biOasis Technologies Inc. (TSX-V: BTI.V – News) today announced test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain which showed that Transcend can deliver an anti-amyloid beta antibody to the brain. The work was conducted on behalf of the Company by the National Research Council of Canada (NRC). Anti-amyloid beta antibodies are currently in clinical trials for the treatment of Alzheimer’s disease (AD). The passive immunization of AD patients using antibodies directed at the Ass peptide is a potential therapeutic strategy aimed at reducing amyloid plaques in the brain. The plaques, consisting of insoluble amyloid ss protein are thought to be responsible for the neuronal cell death and the associated cognitive impairment seen in AD patients. The challenge in using anti-amyloid ss antibodies (and monoclonal antibodies in general) is that these proteins penetrate the blood brain barrier poorly. Approaches that can efficiently deliver these antibodies into the brain may be the key for their use in the treatment of AD.
"There are a number of pharmaceutical companies that are in both early and late stage clinical trials studying anti-amyloid ss antibodies as potential treatments for AD. biOasis has shown over the past several months that its Transcend platform can deliver antibodies (in the case of Herceptin® and now anti-amyloid ss) across the blood-brain barrier in observed higher levels than the antibodies on their own," said Rob Hutchison, CEO. "It may well be that anti-amyloid ss antibodies can provide a treatment for AD, so long as sufficient levels of the antibody can be delivered into the brain. Our Transcend blood-brain delivery platform may play a key role in facilitating the delivery of these antibodies and potentially contribute to the development of new therapeutic approaches to treating AD."
ABOUT TRANSCEND
biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood-brain barrier – Transcend. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation to a range of small molecule and biologic therapeutics. Overcoming the difficulty of delivering therapeutic agents to specific regions of the brain presents a major challenge to treatment of most brain disorders. In its neuroprotective role, the blood-brain barrier functions to hinder the delivery of many potentially important diagnostic and therapeutic agents to the brain. Therapeutic molecules and genes that might otherwise be effective in diagnosis and therapy do not cross the BBB in adequate amounts. It is widely reported that over 95% of all Therapeutic molecules do not cross the blood-brain barrier. To address the unmet clinical need to transport drugs across the blood-brain barrier biOasis intends to license Transcend to multiple corporate partners.
ABOUT BIOASIS:
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing
Cognitest™, a blood test for the diagnosis of Alzheimer’s disease. biOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.
SOURCE: biOasis Technologies
Post Views: 30
